CFRXQ — CONTRAFECT Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: ContraFect Says Selling Securityholder May Offer And Selling Up To 7 Mln Shares In Aggregate Of Common Stock
Brief: Contrafect Announces FDA Clearance Of CF-370 IND Application To Proceed With Phase 1 Clinical Study
Brief: Contrafect Corp Says On Sept 21, Notified By Nasdaq, That Co Not In Compliance With The Minimum Bid Price Requirement
Brief: Contrafect Announces Submission Of Ind Application To The FDA For Its Development Candidate Cf-370
Brief: Contrafect- On Aug 15, Got Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard Transfer Of Listing From Nasdaq
Brief: Contrafect Gets Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard
ContraFect Corp reports results for the quarter ended in June - Earnings Summary
ContraFect Corp expected to post a loss of $1.81 a share - Earnings Preview
Brief: Contrafect Was Notified By Nasdaq That Co Had Regained Compliance With $1.00 Bid Price Requirement
ContraFect Corp soars as Q1 loss narrows
Brief: ContraFect Reports First Quarter 2023 Financial Results And Provides Business Update
ContraFect Corp expected to post a loss of $10.83 a share - Earnings Preview
Brief: ContraFect Announces First Patient Dosed in the Phase 1b/2 Study of Exebacase
Brief: Contrafect Corp Receives Notice Of Continued Listing From Nasdaq
Brief: Contrafect Received Notice Of Delisting From Nasdaq
U.S. STOCKS ON THE MOVE-Alphabet Inc, BlackRock, Moderna
ContraFect Corp reports results for the quarter ended in December - Earnings Summary
Brief: ContraFect Reports Q4 Loss Per Share Of $16.14
Brief: ContraFect Corp Files For Shelf Of Up To 162.8 Million Shares Of Common Stock By Selling Stockholder - SEC Filing